Stock Market Reviews

MIRM (Mirum Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on MIRM (Mirum Pharmaceuticals, Inc.). Explore the news page 5 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Mirum to buy Bluejay for up to $820m in rare liver disease push
  The deal gives Mirum access to Bluejay’s monoclonal antibody brelovitug, which is currently in Phase III trials.
  Dec 9, 2025 - $MIRM
• Sector Update: Health Care Stocks Softer Late Afternoon
  Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 0.6% and th
  Dec 9, 2025 - $MIRM
• Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald
  Cantor Fitzgerald raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $130 from $95 and keeps an Overweight rating on the shares. Mirum’s proposed acquisition of Bluejay Therapeutics for $250M in cash, $300M in stock, and $200M in tiered milestone payments is a “steal,” the analyst tells investors in a research note.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
  Dec 9, 2025 - $MIRM
• Mirum gains a hepatitis D drug in $620M buyout of startup Bluejay
  The deal, which includes another $200 million in potential payouts, hands the California biotech a candidate in late-stage testing for the most severe form of viral hepatitis.
  Dec 8, 2025 - $MIRM
• Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
  FOSTER CITY, Calif., December 08, 2025--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced its entry into a definitive agreement to acquire Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. The transaction would add worldwide rights to brelovitug, a late-stage, fully human monoclonal antibody with Breakthrough Therapy and PRIME designations for chronic hepatitis delta virus (HDV) to Mirum’s portfolio of rare
  Dec 8, 2025 - $MIRM
• Mirum to buy Bluejay for up to $820 million in bet on liver-disease drug
  By Kamal Choudhury Dec 8 (Reuters) - Mirum Pharmaceuticals said on Monday it will buy Bluejay Therapeutics in a deal worth up to $820 million, adding a late-stage experimental drug for a severe liver
  Dec 8, 2025 - $MIRM
• Stronger 2025 Outlook And Fragile X Trial Start Might Change The Case For Investing In Mirum (MIRM)
  Mirum Pharmaceuticals recently reported better-than-expected third-quarter 2025 earnings and revenue, raised its full-year 2025 revenue guidance to US$500 million–US$510 million, and continued to benefit from strong LIVMARLI performance and recently acquired bile acid medicines. At the same time, Mirum advanced its pipeline by enrolling the first participant in the BLOOM Phase 2 trial for Fragile X syndrome, a rare neurodevelopmental condition with no approved treatments, adding a new...
  Dec 4, 2025 - $MIRM
• Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue?
  Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 4, 2025 - $MIRM
• Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026
  Mirum Pharmaceuticals is a mid-cap biotech stock to keep your eyes on.
  Dec 3, 2025 - $MIRM
• MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study
  Mirum enrolls the first participant in its phase II BLOOM study investigating MRM-3379 for treating Fragile X syndrome.
  Dec 2, 2025 - $MIRM